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Abstract 
Background 
Both type 2 diabetes (T2DM) and Bβ448Lys variant of fibrinogen are associated with dense 
fibrin clots, impaired fibrinolysis and increased cardiovascular risk.  
Objectives 
Investigate whether BβArg448Lys adds to vascular risk by modulating fibrin network 
structure and/or fibrinolysis in diabetes. The primary aim was to study effects of 
BβArg448Lys on fibrin network characteristics in T2DM. Secondary aims investigated 
interactions between gender and BβArg448Lys substitution in relation to fibrin clot properties 
and vascular disease. 
Patients/Methods 
Genotyping for BβArg448Lys and dynamic clot studies were carried out on 822 T2DM 
patients enrolled in the Edinburgh Type 2 Diabetes Study. Turbidimetric assays of individual 
plasma samples analysed fibrin clot characteristics with additional experiments conducted 
on clots made from purified fibrinogen, further examined by confocal and electron 
microscopy. 
Results  
Plasma clot lysis time in Bβ448Lys was longer than Bβ448Arg variant (mean±SD; 763±322 
and 719±351 s, respectively; p<0.05). Clots made from plasma-purified fibrinogen of 
individuals with Arg/Arg, Arg/Lys and Lys/Lys genotypes showed differences in fibre 
thickness (46.75±8.07, 38.40±6.04 and 25±4.99 nm, respectively; p<0.001) and clot lysis 
time (419±64, 442±87 and 517±65 s, respectively; p=0.02), directly implicating the 
polymorphism in the observed changes. Women with Bβ448Lys genotype had increased risk 
of cerebrovascular events and were younger compared with Bβ448Arg variant (67.2±4.0 and 
68.2±4.4 years, respectively; p=0.035). 
Conclusions 
Fibrinogen Bβ448Lys variant is associated with thrombotic fibrin clots in diabetes 
independently of traditional risk factors. Prospective studies are warranted to fully 
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understand the role of BβArg448Lys in predisposition to vascular ischaemia in T2DM with 
the potential to develop individualised antithrombotic management strategies. 
 
Keywords: Diabetes Mellitus, Fibrinogen, Genetic Polymorphism, Thrombosis, Vascular 
Diseases 
What is known on this 
topic 
 The common genetic variant of fibrinogen BBArg448Lys 
is associated with significant changes in clot structure 
and fibrinolysis. 
 Diabetes is associated with qualitative and quantitative 
changes in coagulation proteins, resulting in dense fibrin 
networks that are difficult to lyse.  
What this paper adds  We demonstrate that Bβ448Lys variant of fibrinogen is 
associated with thrombotic fibrin networks in a highly 
complex and multifactorial condition such as type 2 
diabetes.  
 Our data also suggest an adverse clinical vascular effect 
of this polymorphism in diabetes, which may be gender 
specific. 
 Further clinical studies are needed to investigate the role 
of this common polymorphism in vascular risk in 
diabetes, which may lead to individualised therapies 
aiming to reduce cardiovascular events, the main cause 
of mortality in this population. 
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Introduction 
Despite advances in medical therapy, cardiovascular complications remain the main 
cause of mortality in diabetes. In addition to increased risk of a first atherothrombotic event, 
prognosis following vascular ischaemia remains poor, in contrast to individuals without 
diabetes, in whom clinical outcome has improved over the past decade (1-7). Current 
evidence indicates that the adverse clinical outcome in diabetes following vascular 
ischaemia is due to more extensive vascular pathology, increased thrombosis potential and 
high prevalence of heart failure, the latter being partly related to atherothrombotic 
complications (1-4;8).  
The prothrombotic environment in diabetes plays a key role in increased 
cardiovascular risk in this population. Formation of an obstructive thrombus in a diseased 
vessel occurs secondary to complex interactions between the cellular and protein phase of 
coagulation (reviewed in (5)). The thrombus, or blood clot, is composed of a backbone of 
fibrin fibres, with embedded platelets and blood cells. Diabetes is associated with qualitative 
and quantitative changes in procoagulant and anti-fibrinolytic proteins leading to fibrin clots 
with tight network structure and resistance to lysis, a structure that has been associated with 
increased cardiovascular risk (6;7;9-17). Moreover, we have recently shown gender 
differences in the association of fibrin network structure with metabolic and cardiovascular 
factors, suggesting a differential fibrin-related thrombosis risk in men and women with 
diabetes (18). 
Fibrinogen BβArg448Lys, a common genetic polymorphism of which the Lys448 
allele has a frequency of 15% to 20% in whites, is associated with both increased vascular 
risk and hypofibrinolysis (9;19-22). Using recombinant techniques, we have previously 
shown that clots made from the Bβ448Lys variant of fibrinogen have a compact structure of 
thin fibres and small pores, with increased stiffness and greater resistance to lysis (9), 
consequently predisposing to a thrombotic environment.  
Taken together, both diabetes and BβArg448Lys variants of fibrinogen induce 
changes in fibrin networks that are associated with increased cardiovascular risk. Despite 
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the relatively high prevalence of diabetes and BβArg448Lys polymorphism, the effect of 
BβArg448Lys on clot structure in diabetes remains unknown. Therefore, the primary aim of 
this study was to identify whether BβArg448Lys has an independent effect on the fibrin 
network in individuals with type 2 diabetes (T2DM). Our secondary aims included the 
analysis of potential gender differences of Bβ448Arg to Lys substitution on clot 
characteristics and the preliminary investigation of the clinical vascular effect of this 
polymorphism in diabetes. 
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Materials and Methods 
 
Study population and genotyping 
The study protocol of the Edinburgh Type 2 Diabetes Study (ET2DM) has been 
described elsewhere (23). Briefly, 1,066 patients with T2DM (age 60–75 years) were 
recruited from a population-based register including patients treated in both primary and 
secondary care after informed consent. The study population has been shown previously to 
be largely representative of all those randomly selected to participate (N=5,454). A total of 
822 plasma samples were available for genotyping and clot structure analysis. 
Blood samples were taken into tubes containing 1ml 0.109M tri-sodium citrate  
anticoagulant to a final volume of 10ml without a tourniquet after a 4-hour fast, usually at 
midday. The first 5ml were used for clinical tests and platelet-poor plasma was separated 
from subsequent samples. Blood was centrifuged at 2,400g for 20 minutes at room 
temperature and plasma was aspirated. DNA was purified from blood samples and 
genotyping for BβArg448Lys variants of fibrinogen was performed as previously described 
(24). 
 
Analysis of fibrinogen levels, plasma clot formation and lysis 
Fibrinogen levels and fibrin clot characteristics were measured in the 822 plasma 
samples, as previously described (18). Plasma levels of fibrinogen were studied by Clauss 
assay. Clot structure/fibrinolysis was assessed by turbidimetric assays. 
 
Fibrinogen purification 
Plasma samples were chosen for each variant (Arg/Arg, Arg/Lys and Lys/Lys; n=12 
samples for each group), which were matched for sex and glycaemic control, measured as 
HbA1C, and pooled. Fibrinogen was purified by affinity chromatography using a calcium-
dependent IF-1 monoclonal antibody and an automated chromatography system, as 
described (9). Samples were dialysed against 100mM NaCl, 50mM Tris, pH 7.4 using 
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dialysis cellulose membrane tubing, size 10 x 6mm, for 2 hours and subsequently overnight. 
Integrity and purity of plasma-purified fibrinogen were analysed by sodium dodecyl sulphate 
(SDS)-polyacrylamide gel electrophoresis (PAGE). Fibrinogen concentration was determined 
and adjusted to a dilution of 1 mg/ml. Four replicates were performed for each variant and 
experiments were repeated on three different occasions. Results are presented as 
mean±standard deviation (SD). 
 
Analysis of clot formation and lysis in a purified system 
A total of 50µl of purified fibrinogen was mixed with 50µl lysis mix (FXIII [ZLB 
Behring] and plasminogen [ERL] in 100mM NaCl, 50mM Tris, pH 7.4). Polymerisation and 
lysis were initiated by the addition of 50µl clotting mix (thrombin [Millipore] and tissue 
plasminogen activator [Technoclone] in 7.5mM CaCl2, 100mM NaCl, 50mM Tris, pH 7.4), at 
ambient temperature in a 96-well plate. Final concentrations in the fibrinogen, clotting and 
lysis mix were 333µg/ml fibrinogen, 22µg/ml FXIII, 25µg/ml plasminogen 0.5U/ml thrombin 
and 0.312µg/ml tissue plasminogen activator. Four replicates were performed for each 
variant and experiments were repeated on 3 different occasions. Increase in turbidity at 
340nm was continuously monitored every 12 seconds on an ELx-808 IU ultramicroplate 
reader over a period of 120 minutes.  
 
Laser scanning confocal microscopy 
Plasma purified fibrinogen (30 µl) was used in the presence of 0.025mg/ml 488 
fluorescent-labelled fibrinogen. Clotting was initiated with 5µl of activation mix (containing 
thrombin in 35mM CaCl2, 50mM Tris, 100mM NaCl, pH 7.4), to the fibrinogen solution. Final 
concentrations in the clotting mix were 400µg/ml fibrinogen and 0.05U/ml thrombin. 
Subsequently, 30µl of this mixture was pipetted into Ibidi slides in duplicate. Clots were 
visualised using Leica TCS SP-2 laser scanning confocal equipment on an inverted DM IRE 
2 microscope with 40x/1.3 oil pH 3 objective lens. At least three areas of 512 x 512 pixels 
were characterised per sample. 
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Electron Microscopy 
Purified fibrinogen (45μl) was clotted upon addition of 5µl of activation mix 
(containing thrombin in 2.5mM CaCl2, 50mM Tris, 100mM NaCl, pH 7.4), to the fibrinogen 
solution in specially devised small, perforated plastic vessels. Final concentrations in the 
clotting mix were 450µg/ml fibrinogen and 0.5U/ml thrombin. Plasma was diluted 1:2 in 
50mM Tris, 100mM NaCl, pH7.4 and clotted with 5µl 0.05M CaCl2, 11U/ml thrombin in 
50mM Tris, 100mM NaCl, pH 7.4. Samples were incubated at room temperature in a moist 
chamber for 2 hours, washed with sodium cacodylate buffer (0.078M cacodylic acid, pH 7.4) 
and subsequently fixed overnight in 2% glutaraldehyde. Clots were recovered and further 
processed by a stepwise dehydration with an acetone gradient and sputter coated with 
platinum palladium in a 208 HR high-resolution sputter coater. Samples were viewed and 
photographed using a field-emission scanning electron microscope (LEO1530 FEGSEM, 
Leo Electron Microscopy) in 3 different areas of each clot. Images were captured using Leo 
32 version 03.0210 software and cropped using Paintshop Pro version 8.0. Fibre diameters 
of all clots were measured with image analysis software package ImageJ 1,23y (National 
Institutes of Health).  
 
Statistical analysis and power calculations 
Exploratory analysis was done using SPSS program version 16. Between-group 
comparisons of normally distributed variables were carried out using t-test, non-normally 
distributed variables were log-transformed before a t-test was carried out. For plasma 
purified samples, where three genotypes were compared, an ANOVA was carried out. Post-
hoc t-tests were then used to report p-values between two groups. The R environment for 
statistical computing was used to fit logistic regression models to identify associations 
between BβArg448Lys polymorphism and vascular disease. The effect of predictors in the 
regression model was characterised using 95% confidence intervals for the odds ratio 
coefficients.   
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Previous work has shown that 10% prolongation in clot lysis time is associated with 
atherothrombotic conditions (18;25;26). To detect a 10% increase in clot lysis time with 
Bβ448Lys variants of fibrinogen, 181 samples were required given the standard deviation of 
the response variable in our cohort of 56% (at p<0.05 with a power of 80%). Given that the 
frequency of Bβ448Lys variant of fibrinogen in our population of 31%, a total of 790 samples 
were required for analysis. Therefore, our cohort of 822 patients has enough power to detect 
a 10% increase in clot lysis time with Bβ448Lys variant of fibrinogen. 
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Results 
Patient characteristics 
Clinical characteristics of patients are described in Table I. The distribution of the three allelic 
fibrinogen variants was as expected; the majority of patients had the Arg/Arg variant 
(n=564), with fewer patients (n=234) having the Arg/Lys, and 24 patients possessing the 
Lys/Lys variant. 
Cardiometabolic risk factors, including blood pressure, body-mass index, waist 
circumference, waist/hip ratio, HbA1c and lipid profile were similar in individuals with the two 
variants of fibrinogen. Treatment was also similar when comparing individuals with 
Bβ448Arg and Bβ448Lys genotypes of fibrinogen (summarised in Table I). 
 
BβArg448Lys and plasma-derived clots 
Bβ448Lys is associated with changes in clot structure and fibrinolysis 
Clot maximum absorbance in carriers of Bβ448Lys was higher than Bβ448Arg (0.37±0.10 
and 0.35±0.10 arbitrary units (au), respectively; p=0.03) and lysis time longer (763±322 and 
719±351 s, respectively; p=0.01). There was no significant difference in lag time between 
Bβ448Arg and Bβ448Lys plasma (528±125 and 523±116 s, respectively; p=0.70). Results 
are summarised in Figure 1A–C. 
 
Bβ448Lys is associated with higher fibrinogen levels than Bβ448Arg 
Fibrinogen levels were higher in individuals with Bβ448Lys variant when compared with 
Bβ448Arg over the whole group (3.70±0.74 and 3.59±0.73 mg/ml, respectively; p=0.03). 
When split by gender, this difference was only significant in women at 3.81±0.70 and 
3.70±0.70 mg/ml for Bβ448Lys and Bβ448Arg, respectively; p=0.01), with no difference 
detected in males (3.52±0.69 and 3.49±0.73 mg/ml, respectively; p=0.67).  
The differences in lysis time and maximum absorbance between the two variants were still 
significant after adjusting for fibrinogen levels in the whole group (p=0.03 and 0.009 
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respectively). Therefore, the differences in lysis time and clot density are unlikely to be due 
to altered fibrinogen levels comparing the two variants of fibrinogen. 
 
BβArg448Lys and fibrinogen-derived clots  
Bβ448Lys is associated with decreased maximum turbidity and impaired lysis 
To further investigate the effects of the polymorphism on clot structure/lysis in the absence 
of other plasma proteins, and in order to control for fibrinogen plasma levels, we undertook 
turbidity and lysis analysis of clots made from pools of Arg/Arg, Arg/Lys and Lys/Lys variants 
of fibrinogen. Purity and integrity of fibrinogen preparations prior to experiments were 
confirmed by SDS-PAGE.  
 
Maximum absorbance. Clot maximum absorbance significantly differed between Arg/Arg, 
Arg/Lys and Lys/Lys fibrinogen variants (p=0.003). Clot maximum absorbance of Arg/Arg 
fibrinogen was significantly greater than Arg/Lys or Lys/Lys fibrinogen (0.0357±0.007, 
0.0321±0.005 and 0.0297±0.004 au, respectively; p=0.05 and 0.001 respectively). Although 
maximum turbidity of clots made from Arg/Lys variant appeared greater than that of Lys/Lys 
fibrinogen, the difference failed to reach statistical significance (p=0.09; Figure 2A).  
 
Fibrinolysis. Lysis time increased in a stepwise manner in clots made from Arg/Arg, Arg/Lys 
and Lys/Lys variants (419±64, 442±87 and 517±65 s, respectively, p=0.02). This difference 
was only significant between Arg/Arg and Lys/Lys fibrinogen (p=0.003), and Arg/Lys and 
Lys/Lys (p=0.05) as shown in Figure 2B.  
 
Bβ448Lys is associated with compact clots and thinner fibrin fibres 
Confocal microscopy. Fibrin networks in hydrated clots made from purified Lys/Lys 
fibrinogen were more compact than those of Arg/Lys or Arg/Arg fibrinogen (Figure 3A). Clot 
density was further assessed using an in-house developed computer macro. Fibrin network 
density significantly differed between Arg/Arg, Arg/Lys and Lys/Lys fibrinogen variants 
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(p<0.001). Fibrin network made from purified Arg/Arg fibrinogen was less dense compared 
with Arg/Lys or Lys/Lys (104±31, 496±60 and 434±50 au, respectively; p<0.001). There was 
no significant difference in clot density between Arg/Lys and Lys/Lys (p=0.2). 
 
Scanning electron microscopy. This technique was employed to study clot ultrastructure and 
fibrin fibre thickness. The more compact clot structure in the presence of Lys allele was 
confirmed, which was also associated with thinner fibres. Fibre thickness significantly 
differed between Arg/Arg, Arg/Lys and Lys/Lys fibrinogen variants (p<0.001). Fibre thickness 
of clots made from purified Arg/Arg, Arg/Lys and Lys/Lys variants was 46.75±8.07, 
38.40±6.04 and 25±4.99 nm, respectively; p<0.001 between all variants (Figure 3B,C) 
consistent with the turbidimetric data presented above (Figure 2A). Similar observations 
were made for plasma samples; fibre thickness of clots made from plasma Arg/Arg, Arg/Lys 
and Lys/Lys variants was 49.76±8.19, 32.08±6.21 and 24.04±6.38 nm, respectively; p<0.001 
by ANOVA and between all variants. 
 
The clinical role of BβArg448Lys variants of fibrinogen 
BβArg448Lys and age  
Mean age of subjects with Bβ448Lys was lower compared with Bβ448Arg across the whole 
group (67.6±4.1 and 68.3±4.2 years, respectively; p=0.02). This age difference was only 
significant in women (67.2±4.0 and 68.2±4.4 years, respectively; p=0.04) and not men 
(67.9±4.23 and 68.4±4.0 years, respectively; p=0.34). Results are summarised in Figure 4. 
There was no significant difference in age between males and females across the whole 
group (68.2±4.1 and 67.9±4.3 years, respectively; p=0.24). 
 
BβArg448Lys and history of vascular ischaemia  
In the whole group, the Bβ448Lys variant was associated with previous cerebrovascular 
incidents and transient ischaemic attacks (odds ratio [OR], 95% confidence interval [CI] 1.87, 
1.13–3.11; p=0.015; n=822). This value was evident even after adjusting for traditional risk 
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factors, including total cholesterol, high-density lipoprotein, cholesterol, HbA1c, blood 
pressure and smoking (OR, 95% CI 1.98, 1.16–3.37; p=0.016). When the group was split by 
gender, the association of Bβ448Lys variant for stroke/transient ischaemic attack was only 
significant in females and not males, whether adjusted (OR, 95% CI 4.18, 1.56–11.22; p 
=0.003 female: OR, 95% CI  1.43, 0.74–2.76; p=0.27 male) or unadjusted (OR, 95% CI 3.69, 
1.49–9.13; p=0.0045 female: OR, 95% CI 1.38, 0.73–2.62; p=0.32 male). Data are 
summarised in Figure 5.  
No association between BβArg448Lys polymorphism and a history of coronary artery 
disease or myocardial infarction was detected in the whole population or when men and 
women were analysed separately. 
 
BβArg448Lys and current vascular pathology 
Carotid intima media thickness was similar in carriers of Bβ448Arg and Bβ448Lys variants 
(1.00±0.23 and 1.04±0.32 mm, respectively; p=0.08), as was ankle-brachial index (ABI) 
(1.00±0.23 and 0.97±0.32, respectively; p=0.09).  
When analysed by gender, intra mural thickness (IMT) was similar in carriers of Bβ448Arg 
and Bβ448Lys in males (1.00±0.34 and 1.05±0.34 mm, respectively; p=0.14) and females 
(1.01±0.33 and 1.04±0.23 mm respectively; p=0.30). ABI was similar in carriers of Bβ448Arg 
and Bβ448Lys in males (1.00±0.17 and 0.98±0.228, respectively; p=0.84) but a difference 
was detected in females (1.01±0.16 and 0.95±0.23, respectively; p=0.03).  
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Discussion 
Diabetes, a prothrombotic condition, is associated with compact fibrin networks and 
resistance to fibrinolysis, which contribute to the increased risk of vascular events in this 
population. Our work is the first study to investigate the functional role of BβArg448Lys 
variants of fibrinogen in individuals with T2DM and we demonstrate an additional effect of 
this polymorphism on clot structure and fibrinolysis.  
There are a number of novel observations emerging from this work in relation to 
individuals with T2DM: i) carriers of Bβ448Lys variant of fibrinogen display compact plasma 
clots and impaired fibrinolysis compared with Bβ448Arg, ii) in a purified system, Bβ448Lys is 
associated with thinner fibrin fibres and trends in impaired fibrinolysis compared with 
Bβ448Arg, supporting a direct role of this polymorphism in changes observed with plasma 
clots, iii) an association between Bβ448Lys variant of fibrinogen and plasma protein level 
was evident but only in women, and iv) carriers of Bβ448Lys variant were younger, 
suggesting early mortality in this group, which may be gender-specific and attributable to 
increased risk of vascular events. 
An inherent difficulty in studying the functional effects of Bβ448Lys variant on clot 
structure and lysis is the association of this polymorphism with plasma fibrinogen levels (20). 
This is believed to be related to linkage disequilibrium of the -448G/A polymorphism with -
455 G/A and -148 C/T polymorphismsBßGly455Ala and BβCys148Thr variants of fibrinogen 
of the β fibrinogen gene, polymorphisms thatwhich determine protein levels, lying in the 5’ 
flanking region and promoter region of the β-chain of fibrinogen, respectively. In the present 
work, the association between Bβ448Lys and fibrinogen levels was only evident in women, 
indicating that environmental factors have stronger effects on fibrinogen levels than the 
BβArg448Lys polymorphism in men with T2DM. Therefore, the genetic influence on 
thrombosis risk can differ in men and women with T2DM, which may have future therapeutic 
implications. 
When plasma samples were studied, clot density was higher and lysis time longer in 
individuals with Bβ448Lys compared with Bβ448Arg variant. Although fibrinogen levels were 
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higher in carriers of Bβ448Lys, correction for protein levels did not affect the role of the 
polymorphism on clot density or lysis time, suggesting a direct effect of the polymorphism on 
fibrin structure and fibrinolysis. To confirm that the observed changes in clot structure/lysis 
with Bβ448Lys variant of fibrinogen are not related to altered plasma protein levels, we have 
undertaken experiments in a purified system and have shown that clot maximum 
absorbance decreases with increasing number of copies of the Bβ448Lys allele. This further 
supports the role of this polymorphism in altered clot structure in individuals with T2DM. 
These turbidimetric data were reinforced by confocal and electron microscopy, showing 
increasing density of the fibrin clot and decreasing fibre thickness with increasing copies of 
the Bβ448Lys allele. Previous work using a recombinant system has shown thinner fibrin 
fibres with Bβ448Lys variant of fibrinogen, but it was unclear whether carrying one allele 
results in an intermediate phenotype, which is demonstrated in this study. Collectively, these 
results confirm the observed changes in plasma clot structure are independent of fibrinogen 
levels and that the genetic variant of fibrinogen studied has an additive effect on the fibrin 
network in individuals with T2DM. Although these findings have potential clinical 
implications, a further limitation of assessing plasma fibrin networks ex vivo to be 
acknowledged is that it ignores the potential influence of platelets, endothelial, or smooth 
muscle cells on clot properties. 
Despite similarities in clot structure using purified and recombinant proteins, clot lysis 
outside the plasma environment showed some inconsistencies. In our previous study, using 
recombinant protein, the difference in clot lysis between the two variants was only evident in 
the plasma environment (9). In contrast, our current study shows differences in clot lysis 
made from the different variants of fibrinogen in the absence of plasma proteins. There are a 
number of possible explanations for this discrepancy. The current work used purified 
fibrinogen, which may have been contaminated with small quantities of plasma proteins not 
detected by SDS-PAGE. Another explanation is related to diabetes-induced post-
translational modifications in fibrinogen that affect clot structure and fibrinolysis (7;27). A 
differential glycation, or other modification such as oxidation, may have occurred in the two 
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variants, resulting in altered clot lysis, particularly as lysine residues are amenable to such 
modifications (28).  
 
One observation from our work suggests that the Bβ448Lys variant is associated 
with adverse clinical outcome, as individuals with Bβ448Lys variant were significantly 
younger than those with the Bβ448Arg variant, which may indicate premature mortality in 
this population. Interestingly, the younger age of carriers of Bβ448Lys variant only applied to 
women, who also demonstrated an increased risk of cerebrovascular events in carriers of 
this polymorphism. This further suggests a gender difference in the interaction between the 
polymorphism and fibrin-related thrombosis risk in individuals with T2DM. Similar gender-
specific association between stroke and Bβ448Lys variant of fibrinogen has been 
documented in a non-diabetic population before (20) and this therefore requires further 
investigation. However, we should be cautious in our interpretations as the study was not 
powered to investigate a clinical effect of this polymorphism. Whilst the difference in age was 
statistically significant, the potential survival benefit with the Arg448 variant is relatively 
modest and future research is needed to clarify whether this polymorphism has a more 
deleterious effect in particular subgroups of patients with diabetes. These findings are 
therefore merely hypothesis-generating and require further investigation in large longitudinal 
studies. We have further identified differences in ABI, a measure of peripheral vascular 
disease, and BβArg448Lys genetic variants of fibrinogen, which was again only evident in 
women. The presence of peripheral vascular disease indicates extensive vascular 
pathology, supporting an association of Bβ448Lys with severity of vascular pathology. 
However, caution should be exercised when interpreting these data, as clinical relevance of 
the documented differences can only be accurately assessed in a longitudinal study that is 
currently ongoing. 
 
In summary, the current work demonstrates that the common genetic variant of 
fibrinogen Bβ448Lys has an additive effect over that of T2DM on fibrin clot structure and 
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fibrinolysis. Moreover, our data suggest an interaction between BβArg448Lys variants of 
fibrinogen, gender and clinical vascular disease that requires further investigation. Overall, 
this study indicates an important role for fibrinogen gene variants in determining thrombosis 
risk even in a complex multifactorial condition such as T2DM. Further clinical studies are 
needed to investigate the role of this common polymorphism in vascular risk in diabetes, 
which may lead to individualised therapies to reduce cardiovascular events, the main cause 
of mortality in this population. 
  
 18 
 
Acknowledgements: 
K. A. Greenhalgh researched data and wrote the manuscript. M. W. Strachan 
reviewed/edited the manuscript. S. Alzahrani researched data. P. D. Baxter researched data 
and reviewed the manuscript. K. Standeven reviewed the manuscript. R Storey 
reviewed/edited the manuscript, R .A. S Ariens reviewed/edited the manuscript. P. J. Grant 
reviewed the manuscript. J. F. Price wrote/reviewed/edited the manuscript. R. A. Ajjan 
researched data and wrote/reviewed/edited the manuscript. 
The authors would like to acknowledge the help of Fladia Phoenix with laboratory 
assistance. 
 
 
  
 19 
 
Reference List 
 
 (1)  Puri R, Kataoka Y, Uno K, et al. The distinctive nature of atherosclerotic vascular 
disease in diabetes: pathophysiological and morphological insights. Curr Diab Rep 
2012; 12: 280–285. 
 (2)  Ferreiro JL, Gomez-Hospital JA, Angiolillo DJ. Platelet abnormalities in diabetes 
mellitus. Diab Vasc Dis Res 2010; 7: 251–259. 
 (3)  Alzahrani SH, Ajjan RA. Coagulation and fibrinolysis in diabetes. Diab Vasc Dis Res 
2010; 7: 260–273. 
 (4)  Mercer BN, Morais S, Cubbon RM, et al. Diabetes mellitus and the heart. Int J Clin 
Pract 2012; 66: 640–647. 
 (5)  Ajjan R, Grant PJ. Coagulation and atherothrombotic disease. Atherosclerosis 2006; 
186: 240–259. 
 (6)  Kannel WB, D'Agostino RB, Wilson PW, et al. Diabetes, fibrinogen, and risk of 
cardiovascular disease: the Framingham experience. Am Heart J 1990; 120: 672–
676. 
 (7)  Pieters M, van Zyl DG, Rheeder P, et al. Glycation of fibrinogen in uncontrolled 
diabetic patients and the effects of glycaemic control on fibrinogen glycation. Thromb 
Res 2007; 120: 439–446. 
 (8)  Hess K, Alzahrani SH, Mathai M, et al. A novel mechanism for hypofibrinolysis in 
diabetes: the role of complement C3. Diabetologia 2012; 55: 1103–1113. 
 (9)  Ajjan R, Lim BC, Standeven KF, et al. Common variation in the C-terminal region of 
the fibrinogen beta-chain: effects on fibrin structure, fibrinolysis and clot rigidity. 
Blood 2008; 111: 643–650. 
 (10)  Jorneskog G, Egberg N, Fagrell B et al. Altered properties of the fibrin gel structure in 
patients with IDDM. Diabetologia 1996; 39: 1519–1523. 
 (11)  Raynaud E, Perez-Martin A, Brun J, et al. Relationships between fibrinogen and 
insulin resistance. Atherosclerosis 2000; 150: 365–370. 
 20 
 
 (12)  Diamant M, Nieuwland R, Pablo RF, et al. Elevated numbers of tissue-factor 
exposing microparticles correlate with components of the metabolic syndrome in 
uncomplicated type 2 diabetes mellitus. Circulation 2002; 106: 2442–2447. 
 (13)  Vaidyula VR, Rao AK, Mozzoli M, et al. Effects of hyperglycemia and 
hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 
ligand. Diabetes 2006; 55: 202–208. 
 (14)  Mansfield MW, Heywood DM, Grant PJ. Circulating levels of factor VII, fibrinogen, 
and von Willebrand factor and features of insulin resistance in first-degree relatives of 
patients with NIDDM. Circulation 1996; 94: 2171–2176. 
 (15)  Ceriello A, Esposito K, Ihnat M, et al. Simultaneous control of hyperglycemia and 
oxidative stress normalizes enhanced thrombin generation in type 1 diabetes. J 
Thromb Haemost 2009; 7: 1228–1230. 
 (16)  Dunn EJ, Philippou H, Ariens RA, et al. Molecular mechanisms involved in the 
resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. 
Diabetologia 2006; 49: 1071–1080. 
 (17)  Watala C, Pluta J, Golanski J, et al. Increased protein glycation in diabetes mellitus is 
associated with decreased aspirin-mediated protein acetylation and reduced 
sensitivity of blood platelets to aspirin. J Mol Med (Berl) 2005; 83: 148–158. 
 (18)  Alzahrani SH, Hess K, Price JF, et al. Gender-specific alterations in fibrin structure 
function in type 2 diabetes: associations with cardiometabolic and vascular markers. 
J Clin Endocrinol Metab 2012; 97: E2282–E2287. 
 (19)  French JK, Van de Water NS, Sutton TM, et al. Potential thrombophilic 
mutations/polymorphisms in patients with no flow-limiting stenosis after myocardial 
infarction. Am Heart J 2003; 145: 118–124. 
 (20)  Carter AM, Catto AJ, Bamford JM, et al. Gender-specific associations of the 
fibrinogen B beta 448 polymorphism, fibrinogen levels, and acute cerebrovascular 
disease. Arterioscler Thromb Vasc Biol 1997; 17: 589–594. 
 21 
 
 (21)  Behague I, Poirier O, Nicaud V, et al. Beta fibrinogen gene polymorphisms are 
associated with plasma fibrinogen and coronary artery disease in patients with 
myocardial infarction. The ECTIM Study. Etude Cas-Temoins sur l'Infarctus du 
Myocarde. Circulation 1996; 93: 440–449. 
 (22)  Jacquemin B, Antoniades C, Nyberg F, et al. Common genetic polymorphisms and 
haplotypes of fibrinogen alpha, beta, and gamma chains affect fibrinogen levels and 
the response to proinflammatory stimulation in myocardial infarction survivors: the 
AIRGENE study. J Am Coll Cardiol 2008; 52: 941–952. 
 (23)  Price JF, Reynolds RM, Mitchell RJ, et al. The Edinburgh Type 2 Diabetes Study: 
study protocol. BMC Endocr Disord 2008; 8: 18. 
 (24)  Marioni RE, Deary IJ, Murray GD, et al. Genetic associations between fibrinogen and 
cognitive performance in three Scottish cohorts. Behav Genet 2011; 41: 691–699. 
 (25)  Undas A, Kolarz M, Kopec G, et al. Altered fibrin clot properties in patients on long-
term haemodialysis: relation to cardiovascular mortality. Nephrol Dial Transplant 
2008; 23: 2010–2015. 
 (26)  Collet JP, Allali Y, Lesty C, et al. Altered fibrin architecture is associated with 
hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc 
Biol 2006; 26: 2567–2573. 
 (27)  Dunn EJ, Ariens RA, Grant PJ. The influence of type 2 diabetes on fibrin structure 
and function. Diabetologia 2005; 48: 1198–1206. 
 (28)  Henschen-Edman AH. Fibrinogen non-inherited heterogeneity and its relationship to 
function in health and disease. Ann N Y Acad Sci 2001; 936: 580–593. 
 
  
 22 
 
Table I. Clinical characteristics and protein levels in carriers of BβArg448Lys variants 
of fibrinogen. The Bβ448Arg group consists of homozygotes for the Bβ448Arg fibrinogen 
variant. The Bβ448Lys group consists of homozygotes for the Bβ448Lys fibrinogen variant 
plus all heterozygotes. SD, standard deviation; T2DM, type 2 diabetes; ACEi, angiotensin-
converting-enzyme inhibitor; ARB, angiotensin receptor blocker. 
 
Figure 1. BβArg448Lys genetic variants of fibrinogen and plasma fibrin networks. The 
Bβ448Arg group consists of homozygotes for the Bβ448Arg fibrinogen variant. The 
Bβ448Lys group consists of homozygotes for the Bβ448Lys fibrinogen variant plus all 
heterozygotes. The following clot structure parameters are shown: (A) Lag time; no 
significant difference with B448 allele (B) Lysis time; significant increase with B448Lys 
variant and (C) Maximum absorbance; significant increase with B448Lys variant. Data 
presented are mean ± SD. 
 
Figure 2. BβArg448Lys genetic variants and fibrin clots prepared from purified 
fibrinogen. (A) Clot maximum absorbance; significant decrease with increasing copies of 
the 448Lys allele. (B) Lysis time; prolongation with increasing copies of the 448Lys allele. 
Data presented are mean ± SD. 
 
Figure 3. Visualisation of fibrin clots prepared from BβArg448Lys genetic variants of 
fibrinogen using purified protein. (A) Laser scanning confocal microscopy (magnification 
x4000), showing more compact clots with increasing copies of B448Lys allele. Scale bars 
represent 50M. (B) Scanning electron micrographs (magnification x30000), demonstrating 
differences in clot structure with the genetic variants of fibrinogen. Scale bars represent 
3M. (C) Fibre thickness showing a decrease with increasing copies of B448Lys allele. 
Data presented are mean ± SD. 
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Figure 4. BβArg448Lys fibrinogen variants and age in individuals with type 2 diabetes. 
The Bβ448Arg group consists of homozygotes for the Bβ448Arg fibrinogen variant. The 
Bβ448Lys group consists of homozygotes for the Bβ448Lys fibrinogen variant plus all 
heterozygotes. (A) Patients with the Bβ448Lys variant were significantly younger than those 
with the Bβ448Arg variant. (B) When split for gender, the age difference comparing the two 
genetic variants of fibrinogen significance was only relevant in women. Data presented are 
mean ± SD.  
 
Figure 5. Predictive value of BβArg448Lys fibrinogen variants for cerebrovascular 
disease. The Bβ448Arg group consists of homozygotes for the Bβ448Arg fibrinogen variant. 
The Bβ448Lys group consists of homozygotes for the Bβ448Lys fibrinogen variant plus all 
heterozygotes. Bβ448Lys fibrinogen was associated with a history of cerebrovascular 
disease in the whole group, which was evident in women only after repeating the analysis by 
gender. Model adjusted for cardiovascular risk factors including total and high density 
lipoprotein cholesterol, HbA1c, systolic and diastolic blood pressure and smoking. Data 
displayed as OR ± 95% CI. OR, odds ratio. 
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Table I 
Variable Bβ448Arg 
(n=564) 
Bβ448Lys 
(n=258) 
p-value 
Age, years (range) 68.3 (60–75) 67.6 (60–75) 0.02 
Duration of T2DM, years (±SD) 8.05 (6.57) 8.21 (6.32) 0.78 
Current smokers, n (%) 
Males, n (%) 
71 (12.6) 
293 (52.0) 
36 (14.0) 
129 (50.0) 
0.67 
0.60 
 
Vascular parameters 
   
Systolic blood pressure, mmHg 
(±SD) 
133.6 (16.6) 132.2 (15.80) 0.21 
Diastolic blood pressure, mmHg 
(±SD) 
69.0 (8.9) 68.5 (8.6) 0.43 
 
Anthropometrics 
   
Body-mass index, kg/m2, (±SD) 31.0 (5.4) 31.9 (5.8) 0.28 
Waist circumference, cm (±SD) 106.3 (13.0) 107.6 (12.5) 0.15 
Waist/hip ratio (±SD) 0.96 (0.08) 0.96 (0.07) 0.77 
 
Metabolic and renal 
   
HbA1c, %/ mmol/mol, (±SD) 7.4 (1.16)/ 57 (134) 7.4 (1.02)/ 57 (11) 0.90 
Plasma glucose, mmol/l (±SD) 7.48 (2.03) 7.62 (1.93) 0.34 
Total cholesterol, mmol/l (±SD) 4.3 (0.88) 4.3 (0.9) 0.76 
High-density lipoprotein 
cholesterol, mmol/l (±SD) 
1.3 (0.35) 1.3 (0.36) 0.37 
Estimated glomerular filtration 
rate, ml/min/m2 (±SD) 
64.4 (14.49) 63.6 (14.4) 0.44 
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Treatment,  
   
Metformin, n (%) 344 (61.0) 142 (55.0) 0.48 
Aspirin, n (%) 364 (64.5) 171 (66.3) 0.82 
Insulin, n (%) 57 (10.1) 33 (12.8) 0.31 
Thiazolidinediones, n (%) 93 (16.5) 45 (17.4) 0.78 
ACEi & ARB, n (%) 383 (67.9) 174 (67.4) 0.95 
Statins, n (%) 477 (84.6) 211 (81.8) 0.76 
Sulfonylureas, n (%) 180 (31.9) 69 (26.7) 0.27 
Nitrates, n (%) 99 (17.6) 44 (17.1) 0.88 
 
